Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMK389 in Moderate to Severe Atopic Dermatitis
NCT04836858Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of CMK-389 in atopic dermatitis (AD), sponsored by Novartis. Started Apr 2021; status: completed.
02
Drugs
CMK-389
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04836858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836858.